Loading...

PE anti-human CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
29E.2A3 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
29E.2A3_PE_CD274_Antibody_FC_091013
PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (clone 29E.2A3) PE (filled histogram) or mouse IgG2b, κ PE isotype control (open histogram).
  • 29E.2A3_PE_CD274_Antibody_FC_091013
    PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (clone 29E.2A3) PE (filled histogram) or mouse IgG2b, κ PE isotype control (open histogram).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
329705 25 tests 95€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329706 100 tests 211€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full length human PD-L1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). 

It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest.

Clone 29E.2A3 does not work in Western blot applications7.

Application References

(PubMed link indicates BioLegend citation)
  1. Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block)
  3. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block)
  4. Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed
  5. Haile, S et al. 2013. J. Immunol. 191:2829.
  6. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed
  7. Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations
  1. Shao L, et al. 2021. Cell Death Discov. 7:145. PubMed
  2. Cui J, et al. 2022. Cancer Cell Int. 22:72. PubMed
  3. Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  4. Kumagai Y, et al. 2020. J Surg Res. 246:52. PubMed
  5. Zhang Z, et al. 2022. Cancer Gene Ther. 29:722. PubMed
  6. Rodda LB, et al. 2022. Cell. 185:1588. PubMed
  7. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  8. He Y, et al. 2023. J Transl Med. 21:25. PubMed
  9. Hajibabaei S, et al. 2023. Sci Rep. 13:1003. PubMed
  10. Zhang W, et al. 2022. Dev Cell. 57:329. PubMed
  11. Jiang G, et al. 2020. Aging (Albany NY). 12:11466. PubMed
  12. Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed
  13. Chen L, et al. 2023. Immunology. 169:204. PubMed
  14. Fox DB, et al. 2023. NPJ Precis Oncol. 7:25. PubMed
  15. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  16. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  17. Yi X, et al. 2023. Signal Transduct Target Ther. 8:107. PubMed
  18. Yang A, et al. 2023. J Immunother Cancer. 11:. PubMed
  19. Lafôrets F, et al. 2023. iScience. 26:106514. PubMed
  20. Hu X, et al. 2023. Nat Biotechnol. . PubMed
  21. Gu T, et al. 2023. Front Immunol. 14:1145028. PubMed
  22. Taylor J, et al. 2023. Front Immunol. 14:1119350. PubMed
  23. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  24. Katsurahara K, et al. 2021. Cancer Sci. 112:1026. PubMed
  25. Geuijen C, et al. 2021. Nat Commun. 12:4445. PubMed
  26. Schott DS, et al. 2017. Oncotarget. 8:72755. PubMed
  27. Huang X, et al. 2021. Nat Nanotechnol. 16:214. PubMed
  28. Zhang H, et al. 2021. Cancer Gene Ther. Online ahead of print. PubMed
  29. Jarosch S, et al. 2022. STAR Protoc. 3:101374. PubMed
  30. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  31. Sucker A, et al. 2017. Nat Commun. 8:15440. PubMed
  32. Liu Y, et al. 2021. Oncogene. 40:2230. PubMed
  33. Sugawara E, et al. 2020. Autophagy. 1.323611111. PubMed
  34. Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed
  35. Fujiwara Y, et al. 2021. Pancreas. 50:405. PubMed
  36. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  37. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  38. Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed
  39. Guan H, et al. 2016. Sci Rep. 6:35651. PubMed
  40. Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
  41. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  42. Zong Z, et al. 2019. Front Immunol. 10:1643. PubMed
  43. Nduom E, et al. 2016. Neuro Oncology. 18: 195 - 205. PubMed
  44. Lee JM, et al. 2022. Lupus Sci Med. 9:. PubMed
  45. Leonard NA, et al. 2021. Cancers (Basel). 13:. PubMed
  46. Bryson BD, et al. 2019. Nat Commun. 10:2329. PubMed
  47. Jutz S, et al. 2016. J Immunol Methods. 430:10-20. PubMed
  48. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  49. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  50. El Ahanidi H, et al. 2022. Front Oncol. 11:795242. PubMed
  51. Jarosch S, et al. 2021. Cell Rep Methods. 1:100104. PubMed
  52. Rolfes V, et al. 2018. Oncotarget. 9:27460. PubMed
  53. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  54. Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed
  55. Hu H, et al. 2022. Exp Ther Med. 24:487. PubMed
  56. Zhang R, et al. 2021. Front Oncol. 10:581733. PubMed
  57. Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed
  58. Mao R, et al. 2020. Cancer Sci. 111:3174. PubMed
  59. Durand-Panteix S, et al. 2012. J Immunol. 189:181. PubMed
  60. Bouleau A, et al. 2022. J Nucl Med. 63:1259. PubMed
  61. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  62. Houtsma R, et al. 2021. STAR Protoc. 2:100864. PubMed
  63. Okita R, et al. 2021. Thorac Cancer. 12:775. PubMed
  64. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  65. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  66. Ye LL, et al. 2020. Annals of Translational Medicine. 8(24):1647. PubMed
  67. Yoshino H, et al. 2021. Curr Issues Mol Biol. 43:153. PubMed
  68. Iwasa M, et al. 2019. Oncotarget. 10:1903. PubMed
  69. Richardson JR, et al. 2018. Front Immunol. 2.182638889. PubMed
  70. Curnock AP, et al. 2021. JCI Insight. 6:. PubMed
  71. Kim DH, et al. 2019. Exp Mol Med. 51:94. PubMed
  72. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  73. Rydyznski Moderbacher C, et al. 2020. Cell. 183(4):996-1012.e19. PubMed
  74. Zhou C, et al. 2021. Mol Ther. 29:1512. PubMed
  75. Ahn A, et al. 2021. Cancers (Basel). 13:. PubMed
  76. Tsuchiya K, et al. 2021. Oncoimmunology. 10:1962656. PubMed
  77. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  78. Rydyznski Moderbacher C, et al. 2022. J Clin Invest. :. PubMed
  79. Guo Q, et al. 2022. Blood Adv. 6:5668. PubMed
  80. Zhang Z, et al. 2022. Clin Transl Med. 12:e1072. PubMed
  81. Dan J, et al. 2016. J Immunol. 197: 983 - 993. PubMed
  82. Lundell A, et al. 2017. Sci Rep. 7:39904. PubMed
  83. Park JA, et al. 2020. J Hematol Oncol. 0.661111111. PubMed
  84. Kwak T, et al. 2020. Cell Reports. 33(13):108571. PubMed
  85. Lei Y, et al. 2021. Clin Transl Immunology. 10:e1231. PubMed
  86. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  87. Xu H, et al. 2010. J Immunol. 185:7340. PubMed
  88. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  89. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  90. Gilardini Montani MS, et al. 2020. Br J Cancer. 123:298. PubMed
  91. Zhou X, et al. 2022. J Nucl Med. 63:536. PubMed
  92. Hu Q, et al. 2021. Nat Biomed Eng. 5:1038. PubMed
  93. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  94. Darga EP, et al. 2021. PLoS One. 16:e0260124. PubMed
  95. Zhang H, et al. 2021. Adv Sci (Weinh). 8:2003404. PubMed
  96. Suzuki D, et al. 2020. Stem Cell Reports. 14:49. PubMed
  97. Padet L, et al. 2014. Immunobiology. 219:687. PubMed
  98. Liang YH, et al. 2021. J Biomed Sci. 28:75. PubMed
  99. Shen C, et al. 2021. BMC Med. 19:283. PubMed
  100. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  101. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  102. Tsukamoto M, et al. 2019. Cancer Sci. 110:310. PubMed
  103. Kenty JH, et al. 2021. STAR Protocols. 2(3):100675. PubMed
  104. Zhang C, et al. 2020. Front Oncol. 0.944444444. PubMed
  105. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
RRID
AB_940366 (BioLegend Cat. No. 329705)
AB_940366 (BioLegend Cat. No. 329706)

Antigen Details

Distribution

T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells

Function
CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.

Gene ID
29126 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD274
Specificity Alt (DOES NOT SHOW ON TDS):
CD274
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD274 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD274 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC,IHC-P,Block
Biotin anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
PE anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
APC anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 421™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Ultra-LEAF™ Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC,IHC,Block
PE/Cyanine7 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Purified anti-human CD274 (B7-H1, PD-L1) (Maxpar® Ready) 29E.2A3 FC,CyTOF®
Brilliant Violet 711™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 605™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
GoInVivo™ Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC,IHC,Block
PE/Dazzle™ 594 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 785™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 510™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
PerCP/Cyanine5.5 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 650™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Alexa Fluor® 594 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 IHC-P
TotalSeq™-A0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-B0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-C0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-D0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
PE/Fire™ 810 anti-human CD274 (B7-H1, PD-L1) Antibody 29E.2A3 FC
PE/Cyanine5 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Spark YG™ 570 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 IHC-P,FC
Go To Top Version: 7    Revision Date: 11.30.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account